P-329 A phase II study of daratumumab with weekly carfilzomib, pomalidomide, and dexamethasone in relapsed and refractory multiple myeloma

Autor:	Yee, Andrew, Nadeem, Omar, Rosenblatt, Jacalyn, Sperling, Adam, Bianchi, Giada, Munshi, Nikhil, O'Donnell, Elizabeth, Branagan, Andrew, Avigan, David, Liegel, Jessica, Harrington, Cynthia, Agyemang, Emerentia, Lively, Kathleen, Packer, Lisette, Han, Samuel, Minsky, Cole, Riadi, Manal, McVey, Cailin, Donnelly, Kaleigh, Smith, Caitlin, Katzeff, Mackenna, Goguen, Amy, Horick, Nora, Richardson, Paul, Raje, Noopur
Zdroj:	In Clinical Lymphoma, Myeloma and Leukemia September 2023 23 Supplement 2:S220-S221
Databáze:	ScienceDirect
Externí odkaz:	Zobrazit plný text záznamu Full Text from ScienceDirect